Related Experiment Video
Updated: Jun 10, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Drug resistance in antiviral therapy
Stephen Locarnini1, Scott Bowden
1Department of R&MD, North Melbourne, Victoria, Australia. stephen.locarnini@mh.org.au
Abstract:
The introduction of nucleos(t)ide analog therapy has seen the emergence of antiviral drug resistance, which has become the main factor limiting the long-term application of these antiviral agents for patients with chronic hepatitis B. The prevention of resistance requires the adoption of strategies that effectively control virus replication and exploit an understanding of the mechanisms and processes that drive the emergence of drug resistance, namely high replication rates, low fidelity of the hepatitis B virus rt/polymerase, selective pressure of the nucleos(t)ide analog, role of replication space (liver turnover), fitness of the mutant, and genetic barrier to the drug.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Treatment Resistant Cancers
Inhibitors of Viral Protein Synthesis
Viral Mutations
Pharmacokinetics: Drug–Food and Drug–Viral Interactions

